Fulgent Genetics (MEX:FLGT) Debt-to-Equity : 0.01 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fulgent Genetics Debt-to-Equity?

Fulgent Genetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was MXN49 Mil. Fulgent Genetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was MXN177 Mil. Fulgent Genetics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was MXN20,748 Mil. Fulgent Genetics's debt to equity for the quarter that ended in Jun. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Fulgent Genetics's Debt-to-Equity or its related term are showing as below:

MEX:FLGT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.06
Current: 0.01

During the past 10 years, the highest Debt-to-Equity Ratio of Fulgent Genetics was 0.06. The lowest was 0.00. And the median was 0.02.

MEX:FLGT's Debt-to-Equity is ranked better than
99.48% of 191 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs MEX:FLGT: 0.01

Fulgent Genetics Debt-to-Equity Historical Data

The historical data trend for Fulgent Genetics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Debt-to-Equity Chart

Fulgent Genetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.02

0.03

0.01

Fulgent Genetics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															-	-	0.01	0.01	0.01

Competitive Comparison of Fulgent Genetics's Debt-to-Equity

For the Diagnostics & Research subindustry, Fulgent Genetics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fulgent Genetics's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Debt-to-Equity falls into.

Fulgent Genetics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Fulgent Genetics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(87.248	+	171.627)	/	19284.46
	=	0.01

Fulgent Genetics's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(49.464	+	176.752)	/	20748.414
	=	0.01

Fulgent Genetics (MEX:FLGT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Fulgent Genetics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (MEX:FLGT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

FLGT:USA 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.